Number of eligible people: CDEC discussed the uncertainty in the volume of individuals with moderately severe to critical hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some patients who will be categorized as possessing gentle or reasonable illness might have a critical bleeding ph